Prestige Consumer Healthcare Inc.
PBHHealthcare|Medical - Pharmaceuticals|US
$42.98
-1.34 (-3.02%)
DCF Value
$259.88
Graham Number
$54.85
Cash / Share
$0.98
Financials
Financial Snapshot
Market Cap
$2.04B
Enterprise Value
$4.11B
Revenue (TTM)
$1.17B
Net Income (TTM)
$155.1M
Cash & Investments
$46.5M
Net Cash
-$2.08B
Free Cash Flow (TTM)
$214.2M
Operating CF (TTM)
$229.8M
Debt/Equity
1.09
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $41.9M | $32.5M | $27.5M | $94.8M | $32.3M | $27.2M | $58.5M | $46.5M | $97.9M | $63.9M | $46.5M | |
| Operating Cash Flow | $147.8M | $210.1M | $189.3M | $217.1M | $235.6M | $259.9M | $229.7M | $248.9M | $251.5M | $257.6M | $229.8M | |
| Free Cash Flow | $144.8M | $197.6M | $178.8M | $202.6M | $213.4M | $250.3M | $221.9M | $239.4M | $243.3M | $246.4M | $214.2M | |
| Capital Expenditure | -$3.0M | -$12.5M | -$10.5M | -$14.6M | -$22.2M | -$9.6M | -$7.8M | -$9.6M | -$8.2M | -$11.2M | -$15.6M | |
| Financing Cash Flow | $561.9M | -$209.0M | -$249.3M | -$131.4M | -$279.4M | -$7.6M | -$185.8M | -$241.0M | -$182.1M | -$156.1M | $1.03B |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $882.1M | $1.04B | $975.8M | $963.0M | $943.4M | $1.09B | $1.13B | $1.13B | $1.14B | $1.09B | $1.17B | |
| Cost of Revenue | $381.8M | $464.7M | $420.2M | $410.8M | $395.9M | $466.2M | $502.4M | $500.9M | $503.3M | $514.1M | $560.1M | |
| Gross Profit | $500.3M | $576.5M | $555.6M | $552.2M | $547.5M | $620.6M | $625.3M | $624.4M | $634.5M | $574.6M | $607.0M | |
| R&D | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| SG&A | $217.5M | $332.2M | $232.8M | $236.3M | $223.7M | $264.8M | $252.4M | $259.5M | $263.9M | $265.2M | $296.2M | |
| Operating Income | $205.6M | $215.9M | $67.5M | $291.2M | $297.4M | $329.9M | -$22.4M | $342.4M | $336.8M | $309.4M | $291.2M | |
| Interest Expense | $93.5M | $106.3M | $105.3M | $96.6M | $82.3M | $64.3M | $69.2M | $67.2M | $47.6M | $42.3M | $66.1M | |
| Pretax Income | $110.8M | $107.1M | -$38.1M | $191.2M | $204.1M | $262.5M | -$93.9M | $276.0M | $284.2M | $257.5M | $212.6M | |
| Net Income | $69.4M | $339.6M | -$35.8M | $142.3M | $164.7M | $205.4M | -$82.3M | $209.3M | $214.6M | $190.3M | $155.1M | |
| EPS (Diluted) | 1.30 | 6.34 | -0.69 | 2.78 | 3.25 | 4.04 | -1.65 | 4.17 | 4.29 | 3.91 | 3.24 | |
| EBITDA | $304.5M | $355.7M | $98.8M | $316.7M | $316.6M | $358.8M | $7.9M | $373.9M | $362.0M | $331.1M | $315.3M | |
| Shares Out. (M) | 53.36 | 53.53 | 52.07 | 51.14 | 50.60 | 50.84 | 49.89 | 50.18 | 50.08 | 48.72 | 47.59 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41.9M | $32.5M | $27.5M | $94.8M | $32.3M | $27.2M | $58.5M | $46.5M | $97.9M | $63.9M | $46.5M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $334.4M | $303.5M | $300.9M | $365.7M | $269.8M | $293.3M | $391.7M | $375.0M | $448.3M | $431.5M | $492.1M | |
| Total Assets | $3.91B | $3.76B | $3.44B | $3.51B | $3.43B | $3.67B | $3.35B | $3.32B | $3.40B | $3.55B | $4.72B | |
| Total Current Liabilities | $162.0M | $123.2M | $127.0M | $149.9M | $122.1M | $143.4M | $160.7M | $117.0M | $106.6M | $120.9M | $168.5M | |
| Long-Term Debt | $2.19B | $1.99B | $1.80B | $1.73B | $1.48B | $1.48B | $1.35B | $1.13B | $992.4M | $994.0M | $2.08B | |
| Total Liabilities | $3.09B | $2.58B | $2.35B | $2.34B | $2.07B | $2.09B | $1.91B | $1.66B | $1.57B | $1.66B | $2.78B | |
| Stockholders' Equity | $822.5M | $1.18B | $1.10B | $1.17B | $1.36B | $1.58B | $1.45B | $1.66B | $1.83B | $1.89B | $1.94B | |
| Retained Earnings | $396.7M | $736.3M | $701.8M | $844.1M | $1.01B | $1.21B | $1.13B | $1.34B | $1.56B | $1.75B | $1.80B |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $147.8M | $210.1M | $189.3M | $217.1M | $235.6M | $259.9M | $229.7M | $248.9M | $251.5M | $257.6M | $229.8M | |
| Capital Expenditure | -$3.0M | -$12.5M | -$10.5M | -$14.6M | -$22.2M | -$9.6M | -$7.8M | -$9.6M | -$8.2M | -$11.2M | -$15.6M | |
| Free Cash Flow | $144.8M | $197.6M | $178.8M | $202.6M | $213.4M | $250.3M | $221.9M | $239.4M | $243.3M | $246.4M | $214.2M | |
| Investing Cash Flow | -$694.6M | -$11.6M | $55.4M | -$16.6M | -$22.2M | -$256.5M | -$11.6M | -$20.1M | -$17.5M | -$136.8M | -$1.33B | |
| Financing Cash Flow | $561.9M | -$209.0M | -$249.3M | -$131.4M | -$279.4M | -$7.6M | -$185.8M | -$241.0M | -$182.1M | -$156.1M | $1.03B | |
| Issuance of Stock | $4.0M | $1.6M | $0.00 | $0.00 | $0.00 | $7.0M | $0.00 | $0.00 | $14.8M | $4.3M | $472.0K | |
| Repurchase of Stock | -$1.4M | -$1.1M | -$50.0M | -$56.7M | -$11.9M | $0.00 | -$50.0M | -$25.0M | -$51.5M | -$156.3M | -$46.5M | |
| Net Debt Issuance | $569.5M | -$209.0M | -$200.0M | -$68.5M | -$251.4M | -$5.6M | -$137.8M | -$227.8M | -$139.5M | $504.0K | $1.11B | |
| Stock Based Comp. | $8.1M | $8.9M | $7.4M | $7.6M | $8.5M | $9.0M | $12.4M | $14.0M | $11.2M | $10.8M | $10.6M | |
| Net Change in Cash | $14.6M | -$9.3M | -$5.0M | $67.2M | -$62.5M | -$5.1M | $31.3M | -$12.0M | $51.4M | -$34.0M | -$72.6M |
Dilution Tracker
Shares Outstanding
47M
5-Year Share Growth
-3.7%
Stock Issuance (TTM)
$472.0K
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 53.36 | 53.53 | 52.07 | 51.14 | 50.60 | 50.84 | 49.89 | 50.18 | 50.08 | 48.72 | 47.59 | |
| Change vs Prior % | — | 0.3% | -2.7% | -1.8% | -1.0% | 0.5% | -1.9% | 0.6% | -0.2% | -2.7% | -2.3% | |
| Stock Issuance | $4.0M | $1.6M | $0.00 | $0.00 | $0.00 | $7.0M | $0.00 | $0.00 | $14.8M | $4.3M | $472.0K | |
| Stock Repurchase | -$1.4M | -$1.1M | -$50.0M | -$56.7M | -$11.9M | $0.00 | -$50.0M | -$25.0M | -$51.5M | -$156.3M | -$46.5M | |
| Stock Based Comp. | $8.1M | $8.9M | $7.4M | $7.6M | $8.5M | $9.0M | $12.4M | $14.0M | $11.2M | $10.8M | $10.6M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 56.7% | 55.4% | 56.9% | 57.3% | 58.0% | 57.1% | 55.4% | 55.5% | 55.8% | 52.8% | 52.0% | |
| Operating Margin % | 23.3% | 20.7% | 6.9% | 30.2% | 31.5% | 30.4% | -2.0% | 30.4% | 29.6% | 28.4% | 25.0% | |
| Net Margin % | 7.9% | 32.6% | -3.7% | 14.8% | 17.5% | 18.9% | -7.3% | 18.6% | 18.9% | 17.5% | 13.3% | |
| EBITDA Margin % | 34.5% | 34.2% | 10.1% | 32.9% | 33.6% | 33.0% | 0.7% | 33.2% | 31.8% | 30.4% | 27.0% | |
| FCF Margin % | 16.4% | 19.0% | 18.3% | 21.0% | 22.6% | 23.0% | 19.7% | 21.3% | 21.4% | 22.6% | 18.4% | |
| ROE % | 8.4% | 28.8% | -3.3% | 12.2% | 12.1% | 13.0% | -5.7% | 12.6% | 11.7% | 10.1% | 8.2% | |
| ROA % | 1.8% | 9.0% | -1.0% | 4.0% | 4.8% | 5.6% | -2.5% | 6.3% | 6.3% | 5.4% | 3.3% | |
| ROIC % | 3.4% | 5.9% | 1.9% | 6.4% | 7.2% | 7.3% | -0.6% | 8.1% | 7.7% | 6.6% | 4.7% | |
| R&D / Revenue % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.4% | 18.0% | -6.3% | -1.3% | -2.0% | 15.2% | 3.8% | -0.2% | 1.1% | -4.3% | |
| Gross Profit | 7.1% | 15.2% | -3.6% | -0.6% | -0.9% | 13.4% | 0.7% | -0.1% | 1.6% | -9.4% | |
| Operating Income | -21.0% | 5.0% | -68.7% | 331.3% | 2.1% | 10.9% | -106.8% | 1627.7% | -1.7% | -8.1% | |
| Net Income | -30.5% | 389.3% | -110.5% | 497.4% | 15.7% | 24.7% | -140.1% | 354.3% | 2.5% | -11.3% | |
| EPS (Diluted) | -30.9% | 387.7% | -110.9% | 502.9% | 16.9% | 24.3% | -140.8% | 352.7% | 2.9% | -8.9% | |
| Operating Cash Flow | -15.2% | 42.2% | -9.9% | 14.7% | 8.5% | 10.3% | -11.6% | 8.4% | 1.0% | 2.4% | |
| Free Cash Flow | -15.2% | 36.5% | -9.5% | 13.3% | 5.3% | 17.3% | -11.3% | 7.9% | 1.6% | 1.3% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A Expense | 18.7% | 52.7% | -29.9% | 1.5% | -5.3% | 18.4% | -4.7% | 2.8% | 1.7% | 0.5% | |
| Total Assets | 32.6% | -3.9% | -8.5% | 2.1% | -2.4% | 7.0% | -8.6% | -1.1% | 2.5% | 4.3% | |
| Book Value / Share | 10.0% | 43.0% | -4.8% | 9.3% | 17.2% | 16.0% | -7.6% | 14.7% | 11.0% | 5.5% | |
| Debt | 35.0% | -9.2% | -9.8% | -1.8% | -14.3% | -0.5% | -9.2% | -16.6% | -8.4% | 0.1% | |
| Diluted Shares | 0.4% | 0.3% | -2.7% | -1.8% | -1.0% | 0.5% | -1.9% | 0.6% | -0.2% | -2.7% |
Valuation
P/E (TTM)13.18
10Y Low / Med / High5.32 / 15.08 / 42.41
P/S1.74
10Y Low / Med / High1.56 / 2.64 / 3.76
P/B1.05
10Y Low / Med / High1.39 / 1.69 / 3.58
EV/EBITDA13.04
10Y Low / Med / High10.54 / 12.46 / 562.96
EV/Revenue3.52
10Y Low / Med / High3.38 / 3.92 / 5.78
P/FCF9.51
10Y Low / Med / High8.52 / 11.65 / 20.33
Intrinsic Value Models (per share)
DCF Value
$259.88
Graham Number
$54.85
Cash / Share
$0.98
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 42.41 | 5.32 | -42.54 | 13.05 | 13.44 | 12.94 | -37.96 | 17.03 | 19.90 | 15.08 | 13.18 | |
| P/S Ratio | 3.34 | 1.72 | 1.56 | 1.93 | 2.35 | 2.45 | 2.77 | 3.17 | 3.76 | 2.64 | 1.74 | |
| P/B Ratio | 3.58 | 1.52 | 1.39 | 1.59 | 1.63 | 1.69 | 2.16 | 2.15 | 2.33 | 1.52 | 1.05 | |
| EV/EBITDA | 16.74 | 10.54 | 33.34 | 11.15 | 11.67 | 11.54 | 562.96 | 12.46 | 14.42 | 11.64 | 13.04 | |
| EV/Revenue | 5.78 | 3.60 | 3.38 | 3.67 | 3.92 | 3.81 | 3.93 | 4.14 | 4.59 | 3.54 | 3.52 |
Analyst Estimates & Quality
Altman Z-Score
1.50
Distress
Piotroski F-Score
5
Moderate
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $1.30B | $1.38B | $1.42B |
| Net Income | $222.4M | $242.2M | $260.7M |
| EPS | $4.58 | $5.13 | $5.34 |
| # Analysts (EPS) | 4 | 5 | 1 |
Dividends
Frequency
Special
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Sep 27, 2018 | Oct 15, 2018 | $0.47 | Special |
| Dec 27, 2013 | $0.31 | Special |
Revenue Segments
By Product
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Analgesics | $119.1M | $119.3M | $119.3M | $117.5M | $117.7M | $113.9M |
| Cough and Cold | $70.6M | $107.1M | $127.0M | $119.0M | $106.2M | $101.9M |
| Dermatologicals | $107.1M | $120.4M | $123.7M | $129.1M | $128.9M | $125.9M |
| Eye and Ear Care | $110.4M | $163.4M | $171.1M | $179.4M | $183.3M | $142.9M |
| Gastrointestinal | $161.1M | $204.6M | $226.6M | $231.6M | $255.9M | $259.8M |
| Oral Care | $101.4M | $97.5M | $97.6M | $96.3M | $95.0M | $101.1M |
| Other OTC | $5.4M | $10.0M | $11.1M | $12.0M | $13.8M | $15.4M |
| Women's Health | $268.1M | $264.5M | $251.4M | $240.4M | $236.8M | $227.8M |
By Geography
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Non-US | $144.3M | $176.7M | $174.5M | $238.9M | $240.2M | $238.3M |
| UNITED STATES | $799.0M | $910.1M | $953.2M | $886.5M | $897.5M | $850.4M |